Evidence map›Paper›PMID 35042692›Full record

ArticleCMAJ open

A province-wide HIV initiative to accelerate initiation of treatment-as-prevention and virologic suppression in British Columbia, Canada: a population-based cohort study.

Ni Gusti Ayu Nanditha, Xinzhe Dong, Hiwot M Tafessu, Lu Wang, Michelle Lu, Rolando Barrios, Julio S G Montaner, Viviane D Lima

Open access · diamondAbstract read
In one paragraph

Article in CMAJ open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size.medRxiv : the preprint server for health sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ni Gusti Ayu NandithaBritish Columbia Centre for Excellence in HIV/AIDS (Nanditha, Dong, Tafessu, Wang, Lu, Barrios, Montaner, Lima); Faculty of Medicine (Nanditha, Montaner, Lima), University of British Columbia, Vancouver, BC.
Xinzhe DongBritish Columbia Centre for Excellence in HIV/AIDS (Nanditha, Dong, Tafessu, Wang, Lu, Barrios, Montaner, Lima); Faculty of Medicine (Nanditha, Montaner, Lima), University of British Columbia, Vancouver, BC.
Hiwot M TafessuBritish Columbia Centre for Excellence in HIV/AIDS (Nanditha, Dong, Tafessu, Wang, Lu, Barrios, Montaner, Lima); Faculty of Medicine (Nanditha, Montaner, Lima), University of British Columbia, Vancouver, BC.
Lu WangBritish Columbia Centre for Excellence in HIV/AIDS (Nanditha, Dong, Tafessu, Wang, Lu, Barrios, Montaner, Lima); Faculty of Medicine (Nanditha, Montaner, Lima), University of British Columbia, Vancouver, BC.
Michelle LuBritish Columbia Centre for Excellence in HIV/AIDS (Nanditha, Dong, Tafessu, Wang, Lu, Barrios, Montaner, Lima); Faculty of Medicine (Nanditha, Montaner, Lima), University of British Columbia, Vancouver, BC.
Rolando BarriosBritish Columbia Centre for Excellence in HIV/AIDS (Nanditha, Dong, Tafessu, Wang, Lu, Barrios, Montaner, Lima); Faculty of Medicine (Nanditha, Montaner, Lima), University of British Columbia, Vancouver, BC.
Julio S G MontanerBritish Columbia Centre for Excellence in HIV/AIDS (Nanditha, Dong, Tafessu, Wang, Lu, Barrios, Montaner, Lima); Faculty of Medicine (Nanditha, Montaner, Lima), University of British Columbia, Vancouver, BC.
Viviane D LimaBritish Columbia Centre for Excellence in HIV/AIDS (Nanditha, Dong, Tafessu, Wang, Lu, Barrios, Montaner, Lima); Faculty of Medicine (Nanditha, Montaner, Lima), University of British Columbia, Vancouver, BC vlima@bccfe.ca.
University of British Columbia · CAAIDS Vancouver · CA

Funding

CIHR PJT-148595CIHR PJT-156147
6 · The paper itself

Abstract

backgroundIn 2010, HIV treatment as prevention (TasP), encompassing widespread HIV testing and immediate initiation of free antiretroviral treatment (ART), was piloted under the Seek and Treat for Optimal Prevention of HIV/AIDS initiative (STOP) in British Columbia, Canada. We compared the time from HIV diagnosis to treatment initiation, and from treatment initiation to first virologic suppression, before (2005-2009) and after (2010-2016) the implementation of STOP.

methodsIn this population-based cohort study, we used longitudinal data of all people living with an HIV diagnosis in BC from 1996 to 2017. We included those aged 18 years or older who had never received ART and had received an HIV diagnosis in the 2005-2016 period. We defined the virologic suppression date as the first date of at least 2 consecutive test results within 4 months with a viral load of less than 200 copies/mL. Negative binomial regression models assessed the effect of STOP on the time to ART initiation and suppression, adjusting for confounders. All

resultsParticipants who received an HIV diagnosis before STOP (

interpretationIn a population with universal health coverage, a TasP intervention was associated with shorter times from HIV diagnosis to treatment initiation, and from treatment initiation to viral suppression. Our results show accelerating progress toward the United Nations' 90-90-90 target of people with HIV who have a diagnosis, those who are on antiretroviral therapy and those who are virologically suppressed, and support the global expansion of TasP to accelerate the control of HIV/AIDS.

Indexed as

Antiretroviral Therapy, Highly ActiveHIV InfectionsPost-Exposure ProphylaxisPreventive Health ServicesTime-to-TreatmentAdultBritish ColumbiaCohort StudiesEarly DiagnosisFemaleHumansMaleOutcome and Process Assessment, Health CareSustained Virologic Response

Identifiers

PMID35042692
PMCPMC8920539
OpenAlexW4205271176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.